Form 4: Director John O'Connor Reports Acquisition of Dividend Equivalent Rights in LeMaitre Vascular

Director John O'Connor acquired dividend equivalent rights related to previously granted stock awards in LeMaitre Vascular.

Summary

• John O'Connor, a director at LeMaitre Vascular, reported the acquisition of dividend equivalent rights.
• These rights are associated with previously granted restricted stock unit and performance share unit awards.
• The dividend equivalent rights vest proportionally with the underlying awards and are economically equivalent to one share of the company's common stock.
• The transactions occurred on December 5, 2024, and are related to awards granted in 2021, 2022, and 2023.

Sentiment

Score: 7

Explanation: The document is a routine disclosure of insider transactions, which is neither positive nor negative. It is a normal part of corporate governance and transparency.

Positives

• The acquisition of dividend equivalent rights aligns the director's interests with those of shareholders.
• The vesting of these rights is tied to the performance and time-based vesting of the underlying stock awards.

Industry Context

This filing is a routine disclosure of insider transactions, which is common for publicly traded companies. It reflects the ongoing compensation practices of LeMaitre Vascular.

Comparison to Industry Standards

• The use of dividend equivalent rights is a common practice in executive compensation packages within the medical device industry.
• Many companies, such as Medtronic and Boston Scientific, use similar equity-based compensation methods to align executive interests with shareholder value.

Stakeholder Impact

• The disclosure provides transparency to shareholders regarding executive compensation.
• The acquisition of dividend equivalent rights does not have a direct impact on employees, customers, or suppliers.

Key Dates

Keywords

dividend equivalent rights, director, insider trading, stock awards, LeMaitre Vascular, LMAT, SEC Form 4